Ana Catarina Alves

List of Publications by Year in Descending Order

35 papers	768 citations	16 h-index	27 g-index
37 ext. papers	916 ext. citations	5.6 avg, IF	4.22 L-index

#	Paper	IF	Citations
35	Performance comparison of different classification algorithms applied to the diagnosis of familial hypercholesterolemia in paediatric subjects.. *Scientific Reports*, **2022**, 12, 1164	4.9	0
34	LDLR variants functional characterization: Contribution to variant classification. *Atherosclerosis*, **2021**, 329, 14-21	3.1	2
33	Applicability of Martin-Hopkins formula and comparison with Friedewald formula for estimated low-density lipoprotein cholesterol in e_COR study population. *Revista Portuguesa De Cardiologia*, **2021**,	1	1
32	Characterization of Two Variants at Met 1 of the Human Gene Encoding the Same Amino Acid but Causing Different Functional Phenotypes. *Biomedicines*, **2021**, 9,	4.8	1
31	Familial hypercholesterolemia **2021**, 323-348		0
30	What Is the Role of the New Index Relative Fat Mass (RFM) in the Assessment of Nonalcoholic Fatty Liver Disease (NAFLD)?. *Obesity Surgery*, **2020**, 30, 560-568	3.7	2
29	The familial hypercholesterolaemia phenotype: Monogenic familial hypercholesterolaemia, polygenic hypercholesterolaemia and other causes. *Clinical Genetics*, **2020**, 97, 457-466	4	15
28	Metabolic Dysfunction and Asthma: Current Perspectives. *Journal of Asthma and Allergy*, **2020**, 13, 237-247	3.1	10
27	Prevalence and risk factors of fatty liver in Portuguese adults. *European Journal of Clinical Investigation*, **2020**, 50, e13235	4.6	4
26	Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 2508-2515	9.4	9
25	Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis. *Genetics in Medicine*, **2018**, 20, 591-598	8.1	51
24	Single-Vesicle Assays Using Liposomes and Cell-Derived Vesicles: From Modeling Complex Membrane Processes to Synthetic Biology and Biomedical Applications. *Chemical Reviews*, **2018**, 118, 8598-8654	68.1	74
23	No Evidence for Lower Levels of Serum Vitamin D in the Presence of Hepatic Steatosis. A Study on the Portuguese General Population. *International Journal of Medical Sciences*, **2018**, 15, 1778-1786	3.7	3
22	Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia. *Atherosclerosis*, **2018**, 277, 448-456	3.1	12
21	Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry. *Atherosclerosis*, **2017**, 262, 8-13	3.1	42
20	Low-density lipoprotein receptor mutational analysis in diagnosis of familial hypercholesterolemia. *Current Opinion in Lipidology*, **2017**, 28, 120-129	4.4	26
19	Clinical and molecular aspects of familial hypercholesterolemia in Ibero-American countries. *Journal of Clinical Lipidology*, **2017**, 11, 160-166	4.9	14

18	Lysosomal acid lipase deficiency: A hidden disease among cohorts of familial hypercholesterolemia?. *Journal of Clinical Lipidology*, **2017**, 11, 477-484.e2	4.9	33
17	Mutational analysis of a cohort with clinical diagnosis of familial hypercholesterolemia: considerations for genetic diagnosis improvement. *Genetics in Medicine*, **2016**, 18, 316-24	8.1	27
16	Hepatitis B and C prevalence in Portugal: disparity between the general population and high-risk groups. *European Journal of Gastroenterology and Hepatology*, **2016**, 28, 640-4	2.2	14
15	The importance of an integrated analysis of clinical, molecular, and functional data for the genetic diagnosis of familial hypercholesterolemia. *Genetics in Medicine*, **2015**, 17, 980-8	8.1	27
14	Structural analysis of APOB variants, p.(Arg3527Gln), p.(Arg1164Thr) and p.(Gln4494del), causing Familial Hypercholesterolaemia provides novel insights into variant pathogenicity. *Scientific Reports* , **2015**, 5, 18184	4.9	28
13	Characterization of the first PCSK9 gain of function homozygote. *Journal of the American College of Cardiology*, **2015**, 66, 2152-2154	15.1	27
12	How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. *Liver International*, **2014**, 34, e111-7	7.9	52
11	Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia. *Human Molecular Genetics*, **2014**, 23, 1817-28	5.6	58
10	Cardiovascular risk assessment of dyslipidemic children: analysis of biomarkers to identify monogenic dyslipidemia. *Journal of Lipid Research*, **2014**, 55, 947-55	6.3	16
9	Advantages and versatility of fluorescence-based methodology to characterize the functionality of LDLR and class mutation assignment. *PLoS ONE*, **2014**, 9, e112677	3.7	29
8	Cardiovascular risk profile of high school students: a cross-sectional study. *Revista Portuguesa De Cardiologia*, **2014**, 33, 525-34	1	5
7	Hypercholesterolemia--a disease with expression from childhood. *Revista Portuguesa De Cardiologia* , **2013**, 32, 379-86	1	5
6	Hypercholesterolemia A disease with expression since childhood. *Revista Portuguesa De Cardiologia (English Edition)*, **2013**, 32, 379-386	0	3
5	In vitro functional characterization of missense mutations in the LDLR gene. *Atherosclerosis*, **2012**, 225, 128-34	3.1	18
4	Update of the Portuguese Familial Hypercholesterolaemia Study. *Atherosclerosis*, **2010**, 212, 553-8	3.1	42
3	Molecular diagnosis of familial hypercholesterolemia: an important tool for cardiovascular risk stratification. *Revista Portuguesa De Cardiologia*, **2010**, 29, 907-21	1	12
2	Genetic diagnosis of familial hypercholesterolaemia: the importance of functional analysis of potential splice-site mutations. *Journal of Medical Genetics*, **2009**, 46, 352-7	5.8	35
1	Familial hypercholesterolaemia in Portugal. *Atherosclerosis*, **2008**, 196, 633-42	3.1	71